patent/EP-1606302-A4

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1606302-A4

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a71dde8f2b278da8d0dbe12742ed5e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d98a0a5089e8eef3aa8d0545aa9e3cf1
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-07049 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
filingDate	2004-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38a795b58e2dd4c4eecccc1a99320f1d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eafe9b90d438be31b75f37d3ac0b33fd
publicationDate	2009-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	EP-1606302-A4
titleOfInvention	TECHNIQUES AND COMPOSITIONS FOR USING SURAMINE, POLYSULFATE PENTOSANE, TELOMERASE ANTISENS AND TELOMERASE INHIBITORS
abstract	The invention provides methods and compositions for inhibiting telomerase activity and treatment of telomerase mediated conditions or diseases. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents, surgery, or radiation in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer.
priorityDate	2003-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5361 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395408

Total number of triples: 30.